BOSTON, MASS., Nov. 12, 2024 – BPGbio, Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced its participation in the inaugural Hit ID Summit: From Targets to Hits in Drug Discovery, in Boston. BPGbio scientist Brian Dill, Ph.D., Director of Proteomics, will present a session titled, “Double the Fun: Chemical Proteomics to Identify Targets on Both Ends of a Novel E2-Based Bifunctional Degrader Platform” on November 14.
The session will highlight the latest developments in the company’s novel E2-based protein homeostasis program and discuss fresh methodologies BPGbio is using in advancing the potential for developing E2-based therapeutics in both oncology and neurology.
“It’s a privilege to be invited to present at this Summit the innovative approaches the BPGbio team is taking to leverage the long considered ‘undruggable’ E2s for Targeted Protein Degradation,” said Dr. Dill. “I’m excited to share with fellow researchers the methodologies we are using in pushing the boundaries of this new field and look forward to further implementing our unique approach in partnering projects.”
TPD has recently emerged as a game-changing approach to address difficult-to-target proteins or protein targets that offer limited clinical benefit through traditional small molecule inhibition. While most conventional TPD strategies rely on the use of E3 ligases, new research has shown that E2 proteins—once considered elusive—can be harnessed for effective and precise protein degradation, opening new avenues for therapeutic intervention.
BPGbio is pioneering this shift in the field by advancing a cutting-edge TPD platform that harnesses E2 enzymes to drive the creation of both bifunctional degraders and monovalent molecular glues. This novel approach is expanding the potential of drug discovery, particularly in areas of oncology and neurology, where traditional methods have fallen short.
Alongside its E2-based strategies, BPGbio’s protein homeostasis program incorporates a proprietary collection of over 1,000 Ro3 fragments, which serve as potential ligands and seed compounds for various E2 targets. The program also includes proprietary ternary structures, computational tools for E2 ligand design, and assays designed to rapidly achieve target specificity and selectivity.
